Senate Bill Aimed At Streamlining Combo Product Regulation
This article was originally published in The Gray Sheet
Executive Summary
A Senate bill would streamline device/drug combination registrations at FDA by letting the agency rely on prior PMAs and approved drug findings to help support new product approvals, among other reforms. It was introduced by Sen. Johnny Isakson, R-Ga., and co-sponsored by Sens. Robert Casey, D-Pa., and Pat Roberts, R-Kansas.
You may also be interested in...
Combo Products Won't Get Special Review Pathway At US FDA Anytime Soon
FDA's Jeffrey Shuren and Janet Woodcock tell a Senate committee that the agency is more concerned with implementing combination product provisions from the 21st Century Cures Act than working on a novel review pathway for device/drug combination products.
21st Century Cures: Device Provisions
Dozens of reforms impacting the medtech sector were signed into law Dec. 13 as part of the 21st Century Cures Act. Here's a breakdown of the provisions most important to device- and diagnostic-makers.
21st Century Cures: Device Provisions
Dozens of reforms impacting the medtech sector were passed by the US House Nov. 30 in a compromise version of the 21st Century Cures Act that is expected to pass the Senate and be signed by President Obama before he leaves office. Here's a breakdown of the provisions most important to device- and diagnostic-makers.